Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors Harboring a BRAF V600 Mutation 1Ovarian Neoplasms 1Neoplasms by Site 1Melanoma 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HER2 Negative Breast Cancer Not Immediately Operated 1Glioma 1Fallopian Tube Neoplasms 1ER+ HER2- Advanced Breast Cancer 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

tucatinib 1trastuzumab biosimilar HLX02 1ribociclib 1pertuzumab 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Fulvestrant 1Docetaxel 1Carboplatin 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Anatomic Stage II Breast Cancer AJCC v8 × ribociclib × Clear all
NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡